To motivate scientific and technological workers in the area, the Beijing Economic and Technological Development Area (BDA) awarded 21 enterprises the honorary title of "Pioneer Port for Scientific and Technological Research".

The award plaque for "Pioneer Port for Scientific and Technological Breakthroughs" [Photo/kfqgw.beijing.gov.cn]

The selected enterprises cover technological innovation enterprises with outstanding achievements in the four leading industries and emerging industries of the BDA, including seven enterprises in the biomedicine and massive health industry. 

Among them, Immunotech Biopharm has played a leading role in the field of cellular immunotherapy, and continuously improved its independent innovation and transformation of scientific and technological achievements. 

Currently, the company's core product under development, EAL? (Amplified Activated Lymphocytes), has become the first cellular immunotherapy product approved for Phase II clinical trials in China and is indicated for solid tumors.

The company's research and development of aT19 injection for acute lymphoblastic leukemia, TCR-T cell injections for solid tumors and other products are at the forefront of the industry.

The R&D Center of Immunotech Biopharm [Photo/kfqgw.beijing.gov.cn]

In the field of next-generation information technology, seven of the selected companies play a role as a fortress of innovation in smart manufacturing, smart logistics, and digital economy. 

"Focusing on the construction of intelligent cloud computing infrastructure, we cooperate with the Academy of Information and Communications Technology, the Chinese Academy of Sciences and other institutions to undertake such research topics as core electronic devices, high-end general-purpose chips and basic software products,” said Fang Yuzhen, a leader of SuperCloud.